Long-Term Results of Surgical Treatment of Patients With Pn0-N1 Non-Small Cell Lung Cancer

Yаblonskiy, Petr; Petrov, Andrey; Zemtsova, Irina; Atyukov, M. A.

doi:10.37469/0507-3758-2017-63-1-99-103

Cited by 6 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…При I стадии полученные результаты для нашей когорты пациентов оказались на 7% меньше при аденокарциноме и идентичны при плоскоклеточном раке; при II стадии на 5% меньше при аденокарциноме и больше на 9% при плоскоклеточном раке легкого; при III стадии почти такие же при аденокарциноме и на 7% больше при плоскоклеточном раке. Сравнимые данные приводятся в исследовании коллег из Российской Федерации [5]. Приведенные различия в выживаемости можно объяснить с позиции характеристик азиатской и европейской популяции, этническими и расовыми особенностями, а также спецификой проводимого лечения [6].…”

Section: анализ рисков для пациентов с нмрлunclassified

Analysis of Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) Taking into Account the Main Prognosis Factors and Histological Subtypes of the Tumor

Шепетько¹

2022

Евразийский Онкологический Журнал

View full text Add to dashboard Cite

Рак легкого остается социально-биологической проблемой. В Республике Беларусь заболеваемость в разные годы составляла от 32 до 45 случаев на 100 000 жителей, смертность – от 29 до 33 на 100 000 населения. Гистоструктура или гистогенез первичной опухоли НМРЛ оказывают непосредственное влияние на результаты лечения.Цель. Оценка выживаемости пациентов с НМРЛ в зависимости от основных его подтипов (плоскоклеточного рака легкого и аденокарциномы), стадии заболевания, пола и возраста.Материалы и методы. В материал для исследования вошли наблюдения за 790 пациентами с НМРЛ, находившимися на лечении в УЗ «Минский городской клинический онкологический диспансер» с 2001 по 2018 г.Выживаемость рассчитывалась по методу Каплана – Мейера, сравнение выживаемости в 2 группах выполнялось по критерию lograng, в 3 и более – по критерию хи-квадрат с критерием значимости p<0,05. Проведен моновариантный и мультивариантный анализ показателей: возраста, пола, TNM, степени дифференцировки опухоли G, гистоструктуры опухоли (аденокарцинома, плоскоклеточный рак легкого). Результаты. На основании анализа прогностических показателей была выделена категория пациентов с крайне неблагоприятным прогнозом (с общей 4-летней выживаемостью 0% (SE 3,6%), медианой ОВ 9,1 мес.). В эту группу входят пациенты с плоскоклеточной карциномой, вовлечением в опухолевый процесс лимфоузлов на стороне поражения N2 и возрастом более 65 лет. Lung cancer continues to be a socio-biological problem. In the Republic of Belarus, the incidence of disease varied from 32 to 45 cases per 100,000 inhabitants over the years, and from 29 to 33 deaths per 100,000 inhabitants. Histostructure or histogenesis of the primary tumor NSCLC have a direct influence on the outcome of treatment.Purpose. Evaluation of the survival rate of patients with NSCLC, depending on its main subtypes (squamous cell lung cancer and adenocarcinoma), disease state, gender and age.Materials and methods. The material for the study included the observation of 790 patients with NSCLC who were being treated in «Minsk City Clinical Oncologic Centre» from 2001 to 2018.Survival was calculated using the Kaplan-Meyer method, comparing survival in 2 groups using lograng, 3 or more using chi-squared and p<0.05. A monovariant and multivariant analysis of indicators was made: age, gender, TNM, degree of differentiation of tumor G, histostructure of the tumor (adenocarcinoma, squamous cell lung cancer).Results. Based on the analysis of predictive measures, a category of patients with an extremely unfavorable prognosis was identified (with a total 4-year survival rate of 0% (SE 3.6%), median ОВ 9.1 months). This group includes patients with squamous cell carcinoma, involvement in the tumor process of lymph nodes on the side of the N2 lesion and age over 65 years.

show abstract

Section: анализ рисков для пациентов с нмрлunclassified

Analysis of Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) Taking into Account the Main Prognosis Factors and Histological Subtypes of the Tumor

Шепетько¹

2022

Евразийский Онкологический Журнал

View full text Add to dashboard Cite

show abstract

“…Зуйков 1 , И.А. Попова 1 1 Челябинский областной клинический центр онкологии и ядерной медицины, Челябинск, Российская Федерация; 2 Южно-Уральский государственный медицинский университет, Челябинск, Российская Федерация АННОТАЦИЯ Обоснование. Проблема диагностики и лечения злокачественных новообразований лёгких является крайне актуальной.…”

Section: повышение качества диагностики и верификации периферических ...unclassified

Section: Improving the Quality Of Diagnosis And Verification Of Perip...unclassified

“…Каждый год в мире выявляется более 1 млн новых случаев рака лёгкого [1,2]. Также необходимо отметить, что, по данным международного агентства по изучению рака, злокачественные новообразования данной локализации ежегодно являются наиболее частой причиной смертности во всём мире [1]. В России в 2020 г. злокачественные новообразования трахеи, бронхов и лёгких составили 16,9% в структуре смертности от онкологической патологии и 9,8% в структуре общей онкологической заболеваемости [3].…”

Section: Improving the Quality Of Diagnosis And Verification Of Perip...unclassified

See 1 more Smart Citation

Improving the quality of diagnosis and verification of peripheral lung neoplasms by using a modified biopsy technique for ultrasonic bronchoscopy (EBUS)

Pushkarev

Важенин²,

Кулаев³

et al. 2022

Russian Journal of Oncology

View full text Add to dashboard Cite

BACKGROUND: The problem of diagnosis and treatment of malignant neoplasms of the lungs is extremely relevant. Verification of the malignant process in the case of peripheral localization of the neoplasm in the lung when using ultrasound bronchoscopy does not exceed 70.6%. AIMS: This study aimed to improve the effectiveness of ultrasound bronchoscopy in the State Medical Institution Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine by introducing into clinical practice a modified biopsy technique for ultrasound bronchoscopy. The technique is patented, patent for invention no. RU2719666 C1. MATERIALS AND METHODS: From 2019 to 2021, a study was conducted based on the endoscopic department of the State Medical Institution Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, which included 137 patients. The patients were divided into two groups: the main group included 66 patients in whose examination FBS with endoussis with biopsy by a modified technique was used; the comparison group included 71 patients who underwent ultrasound bronchoscopy with biopsy by a standard technique. The time of biopsy manipulation according to the standard procedure ranged from 14 to 41 min, averaging 305 min. Ultrasound bronchoscopy with biopsy by a modified technique lasted from 16 to 45 minutes, on average 315 min. RESULTS: In the main group, where FBS with ENDOUSSI with biopsy was used in the diagnosis of patients using a modified technique with endosonographic control of the position of the endoscopic instrument in the pathological focus, the diagnosis of malignant neoplasm was verified in 52 patients (in 78.8% of cases). In the comparison group, where the standard biopsy technique was used in patients with ultrasound bronchoscopy, the diagnosis of malignant neoplasm was verified in 41 patients (in 57.7% of cases). Thus, the verification of peripheral lung malignancies when using a modified biopsy technique increases by 21.1% (p 0.05). FBS with endoussis with biopsy using a modified technique is satisfactorily tolerated by patients and is a relatively safe manipulation. CONCLUSION: modified biopsy technique developed by us with endosonographic control of the position of the endoscopic instrument in the pathological focus during ultrasound bronchoscopy makes it possible to increase the percentage of verification of peripheral lung malignancies by 21.1% (p 0.05). The introduction and widespread use of the modified biopsy technique for ultrasound bronchoscopy in the diagnosis of peripheral lung malignancies will reduce the time of examination of patients and prescribe antitumor treatment earlier.

show abstract

Modified Biopsy Assessment for Endobronchial Ultrasound in Diagnosis of Peripheral Lung Neoplasms

Pushkarev

Важенин

Кулаев

et al. 2022

Kreativnaâ hirurgiâ i onkologiâ

View full text Add to dashboard Cite

Background. Diagnosis and treatment of malignant lung neoplasms are pressing issues. Peripheral lung cancer verification rate with endobronchial ultrasound varies within 30–85 %.Aim. To advance endobronchial ultrasound precision, a modified biopsy technique has been developed and introduced into clinical practice at the Chelyabinsk Regional Clinical Centre for Oncology and Nuclear Medicine. The modification comprises real-time ultrasound image guidance of the biopsy forceps alignment and opening. The technique patent for invention is RU 2719666 C1.Materials and methods. Modified endobronchial ultrasound has been performed in 66 patients with suspected peripheral lung malignancy at the Centre’s Department of Endoscopy within 2019–2021. Bioptic material was delivered for histological and, when necessary, immunohistochemical examination.Results. Malignancy diagnosis was verified in 78.8 % cases. The modified technique is relatively safe, with complications detected in two patients (3.8 % cases) and managed conservatively with success. Discussion. The standard biopsy technique provided for a lung malignancy verification rate of 57.7 % over 2019–2021. Thus, the rate improvement by modified technique is 21.1 %. The modified technique is relatively safe, with complications reported in two patients (3.8 % cases) and managed conservatively with success. Modified endobronchial ultrasound was adequately tolerated, with no increase in patient examination time. The technique can supersede more invasive diagnostic procedures.Conclusion. We believe that the modified technique will improve the power of endobronchial ultrasound, reduce examination time and expedite prescription of special therapies.

show abstract

Long-Term Results of Surgical Treatment of Patients With Pn0-N1 Non-Small Cell Lung Cancer

Cited by 6 publications

References 12 publications

Analysis of Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) Taking into Account the Main Prognosis Factors and Histological Subtypes of the Tumor

Analysis of Treatment of Patients with Non-Small Cell Lung Cancer (NSCLC) Taking into Account the Main Prognosis Factors and Histological Subtypes of the Tumor

Improving the quality of diagnosis and verification of peripheral lung neoplasms by using a modified biopsy technique for ultrasonic bronchoscopy (EBUS)

Modified Biopsy Assessment for Endobronchial Ultrasound in Diagnosis of Peripheral Lung Neoplasms

Contact Info

Product

Resources

About